Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Net Cash Flow (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Net Cash Flow for 2 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 337.1% to $8.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Dec 2025, up 314.28% year-over-year, with the annual reading at $1.6 million for FY2025, 275.1% up from the prior year.
  • Net Cash Flow for Q4 2025 was $8.2 million at Neuphoria Therapeutics, up from -$541033.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $12.6 million in Q1 2025, with the low at -$4.7 million in Q3 2024.